Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMESLE-1
2022-500445-24-00Phase 3Completed
- Sponsor
- RemeGen
- Start
- Sep 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Telitacicept with Placebo (2 arms). Started Sep 2022; status: completed.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2022-500445-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500445-24-00.